Forvis Mazars sponsors FT Live: Global Pharma and Biotech Summit 2025
We are proud to sponsor the FT Live Global Pharma & Biotech Summit — a leading industry event bringing together senior executives, researchers and policymakers to explore the future of healthcare, pharma innovation and global collaboration.
We're attending one of the industry’s most influential gatherings, where leaders in pharma, biotech and life sciences come together to shape the future of healthcare. The summit brings together over 300 senior leaders from across the sector to explore breakthroughs in drug discovery, clinical trials, AI, market access and patient engagement.
Panel spotlight: Global health security – Steering progress on pandemic readinessWe’re proud that Nigel Layton, Global Head of Life Sciences at Forvis Mazars, will be speaking at this year’s summit.
AgendaNigel will join senior leaders from Pfizer and Ecolab to explore how the biopharma sector can prepare for future pandemic threats. With the WHO Pandemic Agreement aiming to strengthen global health security, the panel will address the complex challenges facing the industry, including:
Speakers
|
Connect with Forvis Mazars
Our Pharma & Life Sciences team will be attending and available for one-to-one conversations throughout the summit on:
- Navigating regulatory complexity across global markets
- Embracing AI and digital transformation to accelerate innovation
- Embedding ESG into strategy for long-term resilience and impact
- Optimising deal structures and tax strategies for growth
- Building operational resilience in a fast-evolving environment
Book a meeting with one of our life sciences experts
|
Meet our delegates
Rachael Harper London
Nigel Layton Partner - Head of Pharma & Life Sciences - London
Michelle Olckers Partner - Audit & Assurance - London
Tarifa Simpson Partner – Due Diligence - Manchester
Alice Strevens Director - Sustainability - London
6 Oct 2025
Re-shoring life sciences for a sustainable future
The pandemic, geopolitical tensions and the climate emergency have revealed the vulnerabilities of Europe’s life sciences industry. Relocating pharmaceutical and medtech production is no longer a choice but a strategic necessity to safeguard sovereignty, strengthen competitiveness and ensure long-term sustainability.
6 Jun 2025
The potential of AI in pharma
As with many industries, the pharmaceutical and life sciences sector is embracing artificial intelligence (AI) to drive transformation. The sector is using the technology to reshape drug development, improve organisational processes, support R&D and more.
30 Apr 2025
C-suite barometer: life sciences & pharmaceuticals
In a year marked by global uncertainty, shifting regulations, and fast-moving innovation, leaders in the pharmaceuticals and life sciences sector are redefining their strategic priorities.